ea0049ep1032 | Pituitary - Clinical | ECE2017
Defreyne Justine
, Nota Nienke
, Perreira Cecilia
, Thomas Schreiner
, Daphne Fisher Alessandra
, Guy T'Sjoen
Objective: Hormonal treatment in trans women (MtF transgender persons) in Europe usually consists of estrogens and anti-androgens, e.g. cyproterone acetate (CPA). After initiation of cross-sex hormone therapy, an elevation in serum prolactin levels is frequently observed in trans women, which was previously attributed to estrogen agents. This analysis evaluates whether CPA contributes to the elevation of prolactin in trans women receiving cross-sex hormones.<p class="abste...